Navigation Links
Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
Date:10/10/2008

EMERYVILLE, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will hold a conference call on Monday, October 13, to provide an update on the Viprinex(TM) (ancrod) Phase 3 Trial Program for acute ischemic stroke. Hosting the call will be Paul E. Freiman, president and chief executive officer and Warren W. Wasiewski, chief medical officer.

-- Date: Monday, October 13, 2008

-- Time: 1:00 p.m. (ET), 12:00 p.m. (CT), 10:00 a.m. (PT)

-- Dial-in number: 877-440-5803 U.S. & Canada / 719-325-4942

International

Telephonic Replay: A playback of the conference call will be available

from 1:00 p.m. (ET) on October 13, 2008 to midnight (ET) on October 20,

2008. Replay number: 888-203-1112 U.S. / 719-457-0820 International

Pass code: 9164451

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
2. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
3. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies CEO to Retire on December 31, 2008
5. Neurobiological Technologies Reports Third Quarter Financial Results
6. Neurobiological Technologies Sets Date for Third Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
8. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
9. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
10. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
11. Neurobiological Technologies Sets Date for Research and Development Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... ... Information Management Services ( IMS ) is pleased to announce a major upgrade ... and is so significant it was endowed with a new name, BSI Engage. ... a streamlined layout and a more intuitive format for navigating the system. ...
(Date:2/8/2016)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone live. On Thursday, ... mobile-friendly. Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create ...
(Date:2/5/2016)...  In the pharmaceutical industry the medical affairs function ... activities including the identification and engagement of key thought ... high in the oncology therapeutic area where most treating ... Role of Medical Affairs in Oncology Launch Excellence ." ... find better ways to utilize medical affairs to develop ...
(Date:2/4/2016)... 4, 2016 - New FDA action date of ... New FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast ... decade indicated for the treatment of signs and symptoms of dry ... the potential to be the only product approved in the U.S. in the past decade ...
Breaking Biology Technology:
(Date:2/3/2016)... PUNE, India , February 3, 2016 ... to the new market research report "Automated Fingerprint Identification ... (Tenprint Search, Latent Search), Application (Banking & Finance, Government, ... 2020", published by MarketsandMarkets, the market is expected to ... estimated CAGR of 21.0% between 2015 and 2020. The ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
Breaking Biology News(10 mins):